title: Docking Small Molecules to Predicted Off-Targets of the Cancer Drug Erlotinib Leads to Inhibitors of Lung Cancer Cell Proliferation with Suitable In vitro Pharmacokinetic Properties.
abstract: In an effort to develop a rational approach to identify anti-cancer agents with selective polypharmacology, we mine millions of docked protein-ligand complexes involving more than a thousand cancer targets from multiple signaling pathways to identify new structural templates for proven pharmacophores. Our method combines Support Vector Machine-based scoring to enrich the initial library of 1,592 molecules, with a fingerprint-based search for molecules that have the same binding profile as the EGFR kinase inhibitor erlotinib. Twelve new compounds were identified. In vitro activity assays revealed that three inhibited EGFR with IC(50) values ranging from 250 nM to 200 µM. Additional in vitro studies with hERG, CYP450, DNA and cell culture-based assays further compared their properties to erlotinib. One compound combined suitable pharmacokinetic properties while closely mimicking the binding profile of erlotinib. The compound also inhibited H1299 and H460 tumor cell proliferation. The other two compounds shared some of the binding profile of erlotinib, and one gave the most potent inhibition of tumor cell growth. Interestingly, among the compounds that had not shown inhibition of EGFR, four blocked H1299 and H460 proliferation, one potently with IC(50) values near 1 µM. This compound was from the menogaril family, which reached Phase II clinical trial for the treatment of lymphomas. This suggests that our computational approach comparing binding profile may have favored molecules with anti-cancer properties like erlotinib.
authors.affiliation: Department of Biochemistry and Molecular Biology, Center for Computational Biology and Bioinformatics, Indiana University School of Medicine, and Department of Chemistry and Chemical Biology, Indiana University Purdue University Indianapolis.
authors.forename: Liwei
authors.initials: L
authors.lastname: Li
authors.forename: Jing
authors.initials: J
authors.lastname: Li
authors.forename: May
authors.initials: M
authors.lastname: Khanna
authors.forename: Inha
authors.initials: I
authors.lastname: Jo
authors.forename: Jason P
authors.initials: JP
authors.lastname: Baird
authors.forename: Samy O
authors.initials: SO
authors.lastname: Meroueh
references.citation: Mol Cell Proteomics. 2008 Oct;7(10):2048-60
references.pmid: 18487680
references.citation: J Med Chem. 1968 Mar;11(2):387-8
references.pmid: 5691280
references.citation: Cancer Res. 1957 Jul;17(6):579-96
references.pmid: 13446843
references.citation: Nature. 2010 Jan 14;463(7278):184-90
references.pmid: 20016488
references.citation: Chem Pharm Bull (Tokyo). 1982 May;30(5):1609-17
references.pmid: 7116505
references.citation: Anticancer Res. 1992 Nov-Dec;12(6B):1953-6
references.pmid: 1295442
references.citation: Biosystems. 2006 Feb-Mar;83(2-3):81-90
references.pmid: 16426740
references.citation: N Engl J Med. 2005 Jul 14;353(2):123-32
references.pmid: 16014882
references.citation: Invest New Drugs. 1999;17(2):169-72
references.pmid: 10638487
references.citation: Chem Res Toxicol. 2001 Jun;14(6):611-50
references.pmid: 11409933
references.citation: Trends Pharmacol Sci. 2008 Feb;29(2):62-71
references.pmid: 18190973
references.citation: Nucleic Acids Res. 2010 Jan;38(Database issue):D765-73
references.pmid: 19923229
references.citation: Cell. 2001 Feb 23;104(4):569-80
references.pmid: 11239413
references.citation: J Pharmacobiodyn. 1988 Sep;11(9):630-5
references.pmid: 2464052